Provided by Tiger Fintech (Singapore) Pte. Ltd.

Trevi Therapeutics, Inc.

6.90
-0.0100-0.14%
Post-market: 6.87-0.0300-0.43%17:21 EDT
Volume:1.83M
Turnover:12.75M
Market Cap:667.11M
PE:-14.69
High:7.16
Open:6.87
Low:6.73
Close:6.91
Loading ...

Analysts Offer Insights on Healthcare Companies: Affimed (AFMD), Editas Medicine (EDIT) and Trevi Therapeutics (TRVI)

TIPRANKS
·
16 Dec 2024

Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher

Benzinga
·
13 Dec 2024

Top Midday Gainers

MT Newswires Live
·
13 Dec 2024

Trevi Therapeutics Up Nearly 74%, on Pace for Largest Percent Increase Since March 2020 -- Data Talk

Dow Jones
·
13 Dec 2024

Trevi Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
13 Dec 2024

Trevi Therapeutics trial analysis ‘best case outcome,’ says Needham

TIPRANKS
·
13 Dec 2024

JonesResearch reiterates Buy rating on Trevi following positive CORAL update

TIPRANKS
·
13 Dec 2024

Trevi Therapeutics Phase IIb update a major de-risking event, says B. Riley

TIPRANKS
·
13 Dec 2024

H.C. Wainwright ups Trevi Therapeutics target after ‘best-case’ for CORAL

TIPRANKS
·
13 Dec 2024

Trevi Therapeutics Shares Hit 52-Week High After Positive Trial Analysis

Dow Jones
·
12 Dec 2024

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

Benzinga
·
12 Dec 2024

Trevi Therapeutics Reaches 75% of Enrollment Target for Phase 2B IPF Chronic Cough Study

MT Newswires Live
·
12 Dec 2024

BRIEF-Trevi Therapeutics Announces Positive Outcome From Sample Size Re-Estimation

Reuters
·
12 Dec 2024

Trevi Therapeutics provides update on Phase 2b trial of Haduvio in IPF

TIPRANKS
·
12 Dec 2024

Trevi Therapeutics Inc - Trial Reaches 75% Enrollment, Topline Results Expected in H1 2025

THOMSON REUTERS
·
12 Dec 2024

Trevi Therapeutics Inc - Ssre Recommends Continuation of Coral Trial as Planned

THOMSON REUTERS
·
12 Dec 2024

Trevi Therapeutics Announces Positive Outcome From SAMPLE Size Re-Estimation Resulting in No Change to the Current SAMPLE Size for the Phase 2B Coral Trial in Idiopathic Pulmonary Fibrosis Patients With Chronic Cough

THOMSON REUTERS
·
12 Dec 2024

Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN), Trevi Therapeutics (TRVI) and Vigil Neuroscience Inc (VIGL)

TIPRANKS
·
05 Dec 2024

Trevi Therapeutics selloff on data unwarranted, says H.C. Wainwright

TIPRANKS
·
05 Dec 2024

Companies Like Trevi Therapeutics (NASDAQ:TRVI) Are In A Position To Invest In Growth

Simply Wall St.
·
04 Dec 2024